CY1105507T1 - Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες - Google Patents

Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες

Info

Publication number
CY1105507T1
CY1105507T1 CY20061100930T CY061100930T CY1105507T1 CY 1105507 T1 CY1105507 T1 CY 1105507T1 CY 20061100930 T CY20061100930 T CY 20061100930T CY 061100930 T CY061100930 T CY 061100930T CY 1105507 T1 CY1105507 T1 CY 1105507T1
Authority
CY
Cyprus
Prior art keywords
disease
compounds
diseases
schizophrenia
parkinson
Prior art date
Application number
CY20061100930T
Other languages
English (en)
Inventor
Matthias Gerlach
Corinna Maul
Utz-Peter Jagusch
Bernd Sundermann
Martin Fuhr
Adriaan P. Ijzerman
Miriam Dissen-De Groote
Original Assignee
Grunenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001112197 external-priority patent/DE10112197A1/de
Priority claimed from DE2001153344 external-priority patent/DE10153344A1/de
Application filed by Grunenthal Gmbh filed Critical Grunenthal Gmbh
Publication of CY1105507T1 publication Critical patent/CY1105507T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά υποκατεστημένες πυραζολοπυριμιδίνες της γενικής χημικής δομής (I Α) και (I Β), μεθόδους για την παρασκευή τους, φάρμακα, τα οποία περιέχουν τις ενώσεις αυτές, τη χρησιμοποίηση των ενώσεων αυτών για την παρασκευή φαρμάκων για τη θεραπεία πόνου, επιληψίας, σχιζοφρένειας, νευρο-εκφυλιστικών ασθενειών, ειδικότερα νόσου Alzheimer, νόσου Huntington και νόσου Parkinson, εγκεφαλικών ισχαιμιών και εμφραγμάτων, ψυχώσεων που οφείλονται σε αυξημένη στάθμη αμινοξέων, εγκεφαλικών οιδημάτων, καταστάσεων υποτροφοδοσίας του κεντρικού νευρικού συστήματος, ειδικότερα σε υποξίες, ειδικότερα υποξία νεογέννητων, και ανοξίες, άνοιας AIDS, εγκεφαλομυελίτιδας, του συνδρόμου Tourette, της ασφυξίας κατά τη γέννηση, εμβοών των αυτιών, νευροπαθητικού πόνου, ασθενειών των αναπνευστικών οδών, καρκίνου, καρδιακών αρρυθμιών, ανοσο-διαταραχών και -ασθενειών, νόσου Parkinson, νεφρικής ανεπάρκειας, σχιζοφρένειας, διαταραχών ύπνου, αποπληξίας, θρομβώσεων, ακράτειας ούρων, διαβήτη, ψωρίασης, σηπτικού σοκ, εγκεφαλικών τραυμάτων, γλαυκώματος και/ή ανεπάρκειας λόγω στάσης του αίματος καθώς και φαρμακευτικά σκευάσματα που περιέχουν τις ενώσεις αυτές.
CY20061100930T 2001-03-14 2006-07-05 Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες CY1105507T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2001112197 DE10112197A1 (de) 2001-03-14 2001-03-14 Substituierte Pyrazolo- und Thiazolopyrimidine
DE2001153344 DE10153344A1 (de) 2001-10-29 2001-10-29 Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
PCT/EP2002/002722 WO2002072585A2 (de) 2001-03-14 2002-03-13 Substituierte pyrazolo- und thiazolopyrimidine als analgetika

Publications (1)

Publication Number Publication Date
CY1105507T1 true CY1105507T1 (el) 2010-04-28

Family

ID=26008763

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100930T CY1105507T1 (el) 2001-03-14 2006-07-05 Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες

Country Status (25)

Country Link
US (1) US7135568B2 (el)
EP (2) EP1637533B1 (el)
JP (1) JP2004527508A (el)
KR (1) KR20030082982A (el)
CN (1) CN1318422C (el)
AT (2) ATE328886T1 (el)
AU (1) AU2002302419B2 (el)
BR (1) BR0208244A (el)
CA (1) CA2440760C (el)
CY (1) CY1105507T1 (el)
CZ (1) CZ20032474A3 (el)
DE (2) DE50212652D1 (el)
DK (1) DK1368355T3 (el)
ES (2) ES2263779T3 (el)
HK (1) HK1061034A1 (el)
HU (1) HUP0401211A3 (el)
IL (2) IL157895A0 (el)
MX (1) MXPA03008291A (el)
NO (1) NO20034031L (el)
NZ (2) NZ528639A (el)
PL (1) PL364388A1 (el)
PT (1) PT1368355E (el)
RU (1) RU2003129060A (el)
SK (1) SK11542003A3 (el)
WO (1) WO2002072585A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2004076450A1 (en) * 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Pyrazolopyridine derivates
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
US20080287405A1 (en) * 2004-05-14 2008-11-20 Thannickal Victor J Compositions and Methods Relating to Protein Kinase Inhibitors
TW200618800A (en) * 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
KR100838692B1 (ko) 2007-07-11 2008-06-16 한국화학연구원 7-(3′,4′-디알콕시페닐)-4,5,6,7-테트라히드로피라졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는천식 및 만성폐쇄성 폐질환을 포함한 염증관련 질환,관절염, 아토피 피부염, 암 및 뇌질환의 치료 및 예방을위한 약제학적 조성물
EP2248816B1 (en) * 2008-01-24 2014-10-22 Alla Chem, LLC. 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
EP2248814A4 (en) * 2008-01-24 2011-01-12 Alla Chem Llc SUBSTITUTED CYCLOALKAN [E AND D] PYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND PROCESS FOR THEIR PREPARATION AND THEIR USE
EP3020719B1 (en) * 2008-10-06 2017-09-20 Alla Chem, LLC. Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof and methods for the production and use thereof
US20120135980A1 (en) * 2008-12-22 2012-05-31 Theodros Asberom Gamma secretase modulators
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN102775412B (zh) * 2012-08-21 2013-05-01 四川大学 一种镇静催眠的化合物及其制备方法和用途
CN102977106B (zh) * 2012-12-12 2014-12-10 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
CN105188694B (zh) 2013-03-15 2018-07-31 卓莫赛尔公司 用于治疗疼痛的钠通道调节剂
CA2922851C (en) * 2013-09-10 2023-03-14 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2017066633A1 (en) 2015-10-16 2017-04-20 Eisai R&D Management Co., Ltd. Ep4 antagonists
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
JP7177042B2 (ja) * 2017-04-27 2022-11-22 武田薬品工業株式会社 複素環化合物
CN113354644B (zh) * 2020-03-04 2023-07-04 烟台药物研究所 一类用作dpp-iv抑制剂的吡唑并嘧啶结构的化合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264773A1 (en) 1986-10-16 1988-04-27 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines
US4847256A (en) * 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
ZA903588B (en) * 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
FR2717812B1 (fr) * 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.
FR2722786B1 (fr) * 1994-07-20 1996-08-23 Rhone Poulenc Rorer Sa Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
JP2003288537A (ja) 2000-09-25 2003-10-10 Everyd.Com:Kk 商品宅配システムおよび方法
DE10112197A1 (de) 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Pyrazolo- und Thiazolopyrimidine

Also Published As

Publication number Publication date
CA2440760C (en) 2010-02-09
WO2002072585A2 (de) 2002-09-19
EP1637533B1 (de) 2008-08-13
HUP0401211A3 (en) 2008-03-28
EP1368355A2 (de) 2003-12-10
KR20030082982A (ko) 2003-10-23
IL157895A (en) 2009-12-24
HK1061034A1 (en) 2004-09-03
CN1507447A (zh) 2004-06-23
DE50207103D1 (en) 2006-07-20
ATE404568T1 (de) 2008-08-15
PT1368355E (pt) 2006-09-29
DE50212652D1 (de) 2008-09-25
HUP0401211A2 (hu) 2004-10-28
US7135568B2 (en) 2006-11-14
PL364388A1 (en) 2004-12-13
NZ540574A (en) 2006-11-30
IL157895A0 (en) 2004-03-28
MXPA03008291A (es) 2003-12-11
ES2311920T3 (es) 2009-02-16
NO20034031L (no) 2003-10-21
NZ528639A (en) 2005-07-29
DK1368355T3 (da) 2006-10-09
ATE328886T1 (de) 2006-06-15
EP1368355B1 (de) 2006-06-07
EP1637533A1 (de) 2006-03-22
US20040127508A1 (en) 2004-07-01
CA2440760A1 (en) 2002-09-19
JP2004527508A (ja) 2004-09-09
AU2002302419B2 (en) 2007-01-18
SK11542003A3 (sk) 2004-07-07
CZ20032474A3 (cs) 2003-12-17
CN1318422C (zh) 2007-05-30
WO2002072585A3 (de) 2003-02-20
ES2263779T3 (es) 2006-12-16
RU2003129060A (ru) 2005-04-10
BR0208244A (pt) 2004-03-02
NO20034031D0 (no) 2003-09-11

Similar Documents

Publication Publication Date Title
CY1105507T1 (el) Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες
IL176689A0 (en) Use of memantine for the preparation of a medicament for the treatment of mild and mild-to-moderate alzheimer's disease
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
RU95114405A (ru) Применение рилузола в качестве лекарственного средства для лечения неврологических нарушений, вызванных травмами и способ получения лекарственного средства
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
HK1074046A1 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
BR0207272A (pt) Método de tratamento de doenças ou condições de desmielinação
ZA912652B (en) Use of n-alkylated 1,4-dihydropyridinedicarboxylic acid esters as medicaments,new compounds and processes for their preparation
DE60129322D1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
DE69928521D1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
NO892152L (no) Kondenserte diazepinoner, fremstilling derav og legemidler som inneholder dem.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
Smeraski Clonazepam treatment of multi-infarct dementia
GR3006606T3 (el)
RU97104062A (ru) Применение селегилина для лечения эпилептических заболеваний